World Library  
Flag as Inappropriate
Email this Article

Nereus Pharmaceuticals

Article Id: WHEBN0015315183
Reproduction Date:

Title: Nereus Pharmaceuticals  
Author: World Heritage Encyclopedia
Language: English
Subject: List of companies headquartered in San Diego, Aderis Pharmaceuticals, Zonite Products Corporation, Qualitest, Cortex Pharmaceuticals
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Nereus Pharmaceuticals

Nereus Pharmaceuticals
Private
Industry Pharmaceuticals
Founded San Diego, California, United States (1988)
Founder Michael A. Palladino, Kobi M. Sethna, Stan Fleming, William Fenical
Headquarters San Diego, California, United States
Key people
Michael A. Palladino Ph.D.(Scientific Co-founder, SVP and Chief Technology Officer) Kobi M. Sethna (President, CEO)[1]
Gary Shearman (Chairman of the Board)[2]
G.
Number of employees
36[3]
Website www.nereuspharm.com

Nereus Pharmaceuticals is a marine microbial and other natural sources into small molecule human therapeutics.[4] The major disease area addressed by Nereus is cancer. As of 2008, Nereus has no marketed products and its operating funds have been secured through several rounds of preferred stock sales.[3]

Drug discovery

Until 2004, Nereus used methods licensed from the Fungi.[4] Since 2004, the company has focused on commercializing identified bioactive natural products.[4] As of mid-2007, two compounds were being examined in Phase I clinical trials: NPI-2358 and NPI-0052.[4]

  • Plinabulin (NPI-2358) is a halimide derivative, halimide itself having been isolated from a member of genus Aspergillus.[4][5] This compound appears to selectively disrupt tumour vasculature through interaction with microtubules.[4]
  • NPI-1342 (Acanthoic Acid analog, NPI-1302a-3) is a plant derived orally active small molecule that targets the NF_kB transcript factor pathway. It is significantly active against cancer and inflammatory diseases and is being developed for clinical testing in multiple myeloma and glioblastoma.
  • Salinosporamide A (NPI-0052) is a natural product of Salinispora tropica, a member of the bacterial family Micromonosporaceae that was first isolated in 2002 and taxonomically identified genetically in 2005.[6] NPI-0052 acts as a proteasome inhibitor.[4]

References

  1. ^
  2. ^
  3. ^ a b
  4. ^ a b c d e f g
  5. ^ US 6069146 
  6. ^
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.